Premier Alternatives

Eyconis

Therapeutic Devices · Redwood City, CA · Founded 2023 · Privately Held (backing)

Developer of ophthalmology products designed to improve ophthalmology treatments. Eyconis is based in Redwood City, CA and was founded in 2023. Its last reported valuation was $161 million in Jan 2024. It has raised $85.3 million across 2 recorded rounds; the latest was a $25 million early-stage round in Oct 2025.

Last reported valuation
$160.5M
Oct 2026
Priced at
—
Total raised
$85.3M
Last round
Early Stage VC
Oct 2025

Eyconis key facts

as of Oct 2026
  • Developer of ophthalmology products designed to improve ophthalmology treatments.
  • Eyconis is valued at approximately $160.5M as of Oct 2026 (last reported valuation).
  • It has raised $85.3M across 2 recorded rounds; the latest was Early Stage VC ($25.0M) in Oct 2025.
  • Notable investors include RA Capital Management, Frazier Healthcare Partners, HealthQuest Capital, venBio.
  • Eyconis has filed 1 Form D with the SEC, most recently Feb 2024 ($60.3M sold to 7 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$160.5M

Eyconis's last reported valuation, Jan 2024. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Eyconis with a free account
  • ·Watch Eyconis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Eyconis funding rounds

2 rounds
Oct 2025Early Stage VC$25.0MSEC filing▮
Jan 2024Early Stage VC (Series A)$60.3M▮
Full funding history →

Eyconis valuation

Eyconis's last reported valuation was $161 million in Jan 2024. No priced round, secondary trade or fund mark has surfaced since.

How much has Eyconis raised?

Eyconis has raised $85.3 million across 2 recorded rounds since 2024. The largest was a $60.3 million Series A in Jan 2024; the most recent was a $25 million early-stage round in Oct 2025.

Eyconis has filed 1 Form D with the SEC, most recently in Feb 2024 ($60.3 million sold to 7 investors).

Eyconis investors

4 investors are on record for Eyconis, including RA Capital Management, Frazier Healthcare Partners, HealthQuest Capital and venBio. By type, the record holds 2 venture capital firms, 1 asset manager and 1 growth equity firm. The early-stage round in Oct 2025 drew 7 investors.

Comparable companies

Comparable therapeutic devices names by valuation on PrivateMarketView: Soufflé Therapeutics ($345 million), Galvanize Therapeutics ($300 million) and Materna Medical ($110 million).

About Eyconis

Developer of ophthalmology products designed to improve ophthalmology treatments. The company is focused on developing, manufacturing, and commercializing transcon ophthalmology assets globally, enabling clients to leverage the therapies for retinal diseases, such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA).

Industry
Therapeutic Devices
Sector
Healthcare
HQ
Redwood City, CA, United States
Founded
2023
Employees
39
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.